Mirae Asset Nifty 500 Healthcare ETF share price
AMFI: 154169ISIN: INF769K01QA6Mirae Asset Mutual FundETFs
Close ₹21.15up ₹0.07 (0.33%)
Close on 29 Oct 2026, traded as HEALTHCARE. Day's range ₹20.99 to ₹21.21, 23,481 units traded.
52-week range of traded prices to 29 Oct 2026
₹17.18Low, 2 Apr 2026₹23.80High, 23 Sep 2026
- NAVNet asset value (NAV). What one unit of the fund is worth: everything the fund owns, less what it owes, divided by the units held by investors, worked out once a day after the market closes. Net asset value (NAV) in the glossary
- ₹21.151429 Oct 2026
- Discount to NAVPremium or discount. How far the ETF's closing price on the exchange was above or below its NAV the same day: the close divided by that day's NAV, less one. Above the NAV is a premium, below it a discount. Premium or discount in the glossary
- −0.01%29 Oct 2026
- Fund sizeAssets under management. The money the fund manages for all its investors, across every plan, at the end of the month. Assets under management in the glossary
- ₹15 CrSep 2026
- Expense ratioTotal expense ratio. What the fund charges each year as a share of the money invested, taken out of the NAV every day, so the returns shown are already after it. Total expense ratio: how it is worked out
- 0.35%21 Oct 2026
- Exit loadExit load. A charge, as a share of the amount redeemed, on units sold before a set period has passed since they were bought. Exit load in the glossary
- None
- P/EP/E. What the fund pays for each rupee of yearly profit its companies earn: the total value of its shares divided by those companies' last four quarters of profit, each in proportion to what the fund holds. The profit leaves out one-off items (exceptional items and businesses sold or demerged), so one company's one-off gain cannot pull the fund's P/E down. A loss-making company lowers the profit. Shown when at least 80% of the fund's shares are counted. P/E in the glossary
- 41.630 Sep 2026
- Risk levelRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month. Riskometer in the glossary
- Very HighAug 2026
- HoldingsHoldings. The number of different securities in the fund's latest monthly portfolio: shares, bonds, money market paper and units of other funds, not cash, overnight lending or futures. Holdings in the glossary
- 4430 Sep 2026
- Offer openedNew fund offer opened. The day the fund's new fund offer opened for investors to apply; units are allotted when it closes. New fund offer opened in the glossary
- 27 Jan 2026
Mirae Asset Nifty 500 Healthcare ETF returns
Over each window to 29 Oct 2026
| Over | ReturnTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). Trailing return: how it is worked out | BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back. Benchmark in the glossary |
|---|---|---|
| 1 week | +4.95% | +4.95% |
| 1 month | −2.30% | −2.29% |
| 3 months | −2.18% | −2.14% |
| 6 months | +11.19% | +11.30% |
| 1 year | Needs a year | – |
₹10,000 put in on 11 Feb 2026 is ₹11,468 at the NAV of 29 Oct 2026Growth of ₹10,000. What ₹10,000 put in at the NAV of the first day would be worth at the latest NAV, after the fund's expenses and before tax and any exit load. Growth of ₹10,000 in the glossaryOver a year and longer, a return is the yearly rate. Benchmark: Nifty500 Healthcare TRI, over the same days as the fund.
Tracking error
Against Nifty 500 Healthcare - TRI, as on 30 Sep 2026.
Against its index, by window
| Measure | This fund |
|---|---|
| Tracking errorTracking error. How much an index fund's daily returns differed from its index's, stated as a yearly figure. Tracking error in the glossary | 0.18% |
| Difference since launch | −0.30 pts |
Difference: the fund's return less the index's, in percentage points.
Premium or discount to NAV, each session, HEALTHCARE
- Premium
Highest +0.32%, 27 Oct 2026.Lowest −0.44%, 21 Oct 2026.
Mirae Asset Nifty 500 Healthcare ETF expense ratio and exit load
Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.
- 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies. Expense ratio, 30-day average in the glossary
- 0.35%Over the last 30 days filed
Total expense ratio, month by month
Expense ratio highest 0.43%, Jun 2026.Expense ratio lowest 0.11%, Mar 2026.
What the expense ratio is made of
| Part | A year |
|---|---|
| Base expense ratioBase expense ratio. The part of the expense ratio that pays the fund house and the distributor, before brokerage, transaction costs, levies and GST. Base expense ratio in the glossary | 0.16% |
| Brokerage | 0.01% |
| Transaction costs | None |
| Statutory levies | 0.18% |
Per cent of assets a year, filed for 28 Oct 2026. The parts add up to that day's total.
Mirae Asset Nifty 500 Healthcare ETF AUM
₹ crore, every plan of the fund together.
- Average assetsAverage assets under management. The money the fund managed, averaged over every day of the quarter, added up across its plans.
- ₹14 CrQuarter to Sep 2026
Average assets by quarter
The latest quarter is the largest since the quarter to Mar 2026.
Assets at each month end
The latest month end is the highest since Feb 2026.Lowest ₹7 Cr, Feb 2026.
Mirae Asset Nifty 500 Healthcare ETF portfolio
Portfolio disclosed for 30 Sep 2026.
Holdings on 30 Sep 2026
| Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month. Large, mid and small cap in the glossary | Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. Weight in the fund in the glossary | Held since. The first month end of the fund's current run of holding this position; marked "or earlier" where that month is the fund's first portfolio on record or the first after a gap in its portfolios. Held since in the glossary | |||
|---|---|---|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | Large cap13th | 10.13% | 1.56 | 8,570 | Feb 2026or earlier |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | Large cap50th | 8.76% | 1.35 | 1,448 | Feb 2026or earlier |
| Apollo Hospitals EnterpriseHealthcare Services | Large cap97th | 6.24% | 0.96 | 1,173 | Feb 2026or earlier |
| Laurus LabsPharmaceuticals & Biotechnology | Mid cap171st | 5.72% | 0.88 | 4,437 | Feb 2026or earlier |
| CiplaPharmaceuticals & Biotechnology | Large cap99th | 5.62% | 0.86 | 6,412 | Feb 2026or earlier |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | Mid cap104th | 5.58% | 0.86 | 6,949 | Feb 2026or earlier |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | Large cap61st | 5.24% | 0.80 | 1,676 | Feb 2026or earlier |
| Max Healthcare InstituteHealthcare Services | Mid cap111th | 5.13% | 0.79 | 8,479 | Feb 2026or earlier |
| LupinPharmaceuticals & Biotechnology | Mid cap105th | 3.66% | 0.56 | 2,767 | Feb 2026or earlier |
| Aurobindo PharmaPharmaceuticals & Biotechnology | Mid cap138th | 3.43% | 0.53 | 3,148 | Feb 2026or earlier |
| Fortis HealthcareHealthcare Services | Mid cap156th | 2.98% | 0.46 | 5,936 | Feb 2026or earlier |
| Glenmark PharmaceuticalsPharmaceuticals & Biotechnology | Mid cap176th | 2.61% | 0.40 | 1,716 | Feb 2026or earlier |
| Alkem LaboratoriesPharmaceuticals & Biotechnology | Mid cap164th | 2.31% | 0.35 | 687 | Feb 2026or earlier |
| Zydus LifesciencesPharmaceuticals & Biotechnology | Mid cap114th | 2.14% | 0.33 | 2,823 | Feb 2026or earlier |
| Mankind PharmaPharmaceuticals & Biotechnology | Mid cap119th | 2.10% | 0.32 | 1,291 | Feb 2026or earlier |
Weight is per cent of the fund's net assets; value in ₹ crore.
Cash and receivables on 30 Sep 2026
| TREPS | 0.13% | 0.02 |
| Net Receivables / (Payables) | −0.09% | −0.01 |
Weight is per cent of the fund's net assets; value in ₹ crore.
- Largest holdingLargest holding. The share of the fund in its single largest position, cash and futures not counted as positions. Largest holding in the glossary
- 10.13%Sun Pharmaceutical Industries
- Top 5 holdingsTop 5 holdings. The share of the fund held in its five largest positions. Top 5 holdings in the glossary
- 36.47%
- Top 10 holdingsTop 10 holdings. The share of the fund held in its ten largest positions. Top 10 holdings in the glossary
- 59.50%
- Effective holdingsEffective number of holdings. The number of equal-sized positions that would be as concentrated as the fund's actual weights. Effective number of holdings in the glossary
- 21.9Taken over 99.96% of the fund
Asset allocation
Asset allocation. What the fund owns, by kind of asset, each as a share of its net assets; futures and options are shown beside it, not in it, since they are contracts rather than assets bought. Asset allocation in the glossary- Indian shares99.96%
- Cash and receivables0.04%
Per cent of the fund's net assets.
Large, mid and small cap
- Large cap36.00%
- Mid cap45.66%
- Small cap18.34%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026.
Sector allocation
Sector weight. The fund's shares grouped by the business each company is in, less the futures sold on them, each group as a share of the fund's net assets. Sector weight in the glossary1sector
- Healthcare99.96%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026.
Sector allocation month by month
| 8 months | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Healthcare44 companies | 99.96% | 99.95% | 99.81% | 99.90% | 99.92% | 99.93% | 99.94% | 99.87% |
Per cent of the fund's net assets, less the futures sold on its shares, at each month end, Feb 2026 to Sep 2026.
Bought and sold
Sep 2026 against Aug 2026, position by position.
Positions changed, month by month
- New
- Added
- Trimmed
- Sold out
- New positionsNew positions. Holdings in this month's portfolio that were not in the month before. New positions in the glossary
- 10.43% of the fund
- Sold outSold out. Holdings in last month's portfolio that are gone from this one, other than a bond or deposit repaid on its due date. Sold out in the glossary
- 52.16% of the fund before
- Added toAdded to. Holdings with more units than the month before. Where the fund states no units, a weight that rose by more than a tenth. Added to in the glossary
- 43
- TrimmedTrimmed. Holdings with fewer units than the month before. Where the fund states no units, a weight that fell by more than a tenth. Trimmed in the glossary
- 0
- UnchangedUnchanged. Holdings with the same number of units as the month before. Their weight can still move with the price. Unchanged in the glossary
- 0
- Traded at leastTraded at least. The smaller of the weight bought in new positions and the weight sold out of old ones, cash left out: the least the fund must have bought and sold in the month. Traded at least in the glossary
- 0.43%
- Weight that movedWeight that moved. Half the sum of every position's change in weight between the two month ends, new and sold positions included; price moves alone raise it. Weight that moved in the glossary
- 3.74%
Changes in Sep 2026
| What changed. New: not held the month before. Added or trimmed: more or fewer units than the month before, or, where no units are stated, a weight that moved by more than a tenth. Sold out: held the month before, gone now. Matured: a bond or deposit whose repayment date fell between the two portfolios, so it was repaid rather than sold (one sold in its last days reads the same). What changed in the glossary | Change in weight. The holding's weight this month less its weight the month before, in percentage points; a price move alone changes it. Change in weight in the glossary | ||||
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories | Added | 5.58% | 4.99% | +0.59 pts | +429 |
| Jubilant Pharmova | Sold out | – | 0.50% | −0.50 pts | −861 |
| Pfizer | Sold out | – | 0.50% | −0.50 pts | −162 |
| Eris Lifesciences | Sold out | – | 0.50% | −0.50 pts | −577 |
| Indegene | Sold out | – | 0.45% | −0.45 pts | −1,106 |
| Laurus Labs | Added | 5.72% | 5.28% | +0.44 pts | +276 |
| Rubicon Research | New | 0.43% | 0.00% | +0.43 pts | +405 |
| Fortis Healthcare | Added | 2.98% | 3.35% | −0.38 pts | +363 |
| Max Healthcare Institute | Added | 5.13% | 5.50% | −0.37 pts | +519 |
| Apollo Hospitals Enterprise | Added | 6.24% | 6.50% | −0.26 pts | +72 |
| Sun Pharmaceutical Industries | Added | 10.13% | 9.90% | +0.24 pts | +1,049 |
| Divi's Laboratories | Added | 8.76% | 8.53% | +0.23 pts | +89 |
| Blue Jet Healthcare | Sold out | – | 0.21% | −0.21 pts | −545 |
| Wockhardt | Added | 1.30% | 1.10% | +0.19 pts | +58 |
| Biocon | Added | 1.91% | 2.08% | −0.17 pts | +309 |
Weights are per cent of the fund's net assets; a change in weight is in percentage points.
Holdings month by month
| Holding | Oct 25 | Nov 25 | Dec 25 | Jan 26 | Feb 26 | Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries | – | – | – | – | 10.02% | 10.03%Added | 9.71%Added | 9.22%Added | 9.78%Added | 10.06%Cut | 9.90%Added | 10.13%Added |
 Divi's Laboratories | – | – | – | – | 6.80% | 6.67%Added | 6.86%Added | 6.72%Added | 6.22%Added | 7.36% | 8.53%Added | 8.76%Added |
 Apollo Hospitals Enterprise | – | – | – | – | 6.72% | 6.75%Added | 6.53%Added | 6.68%Added | 6.65%Added | 6.63% | 6.50%Added | 6.24%Added |
 Laurus Labs | – | – | – | – | 3.49% | 3.41%Added | 3.56%Added | 4.20%Added | 4.39%Added | 5.08%Cut | 5.28%Added | 5.72%Added |
 Cipla | – | – | – | – | 6.33% | 6.08%Added | 6.12%Added | 6.25%Added | 6.13%Added | 5.96%Cut | 5.62%Added | 5.62%Added |
 Dr. Reddy's Laboratories | – | – | – | – | 6.54% | 6.75%Added | 6.70%Added | 6.30%Added | 6.15%Added | 5.03%Cut | 4.99%Added | 5.58%Added |
 Torrent Pharmaceuticals | – | – | – | – | 3.78% | 3.90%Added | 3.64%Added | 3.66%Added | 3.60%Added | 5.40%Added | 5.27%Added | 5.24%Added |
 Max Healthcare Institute | – | – | – | – | 6.78% | 6.32%Added | 6.14%Added | 5.70%Added | 6.25%Added | 5.88%Cut | 5.50%Added | 5.13%Added |
 Lupin | – | – | – | – | 4.66% | 4.95%Added | 4.65%Added | 4.36%Added | 4.37%Added | 4.22% | 3.77%Added | 3.66%Added |
 Aurobindo Pharma | – | – | – | – | 2.85% | 3.22%Added | 3.23%Added | 3.16%Added | 3.25%Added | 3.14%Cut | 3.37%Added | 3.43%Added |
 Fortis Healthcare | – | – | – | – | 4.10% | 3.66%Added | 4.00%Added | 3.84%Added | 3.71%Added | 3.54%Cut | 3.35%Added | 2.98%Added |
 Glenmark Pharmaceuticals | – | – | – | – | 2.69% | 2.83%Added | 3.01%Added | 2.72%Added | 2.47%Added | 2.42% | 2.65%Added | 2.61%Added |
 Alkem Laboratories | – | – | – | – | 2.75% | 2.73%Added | 2.63%Added | 2.55%Added | 2.42%Added | 2.42% | 2.21%Added | 2.31%Added |
 Zydus Lifesciences | – | – | – | – | 1.93% | 1.92%Added | 1.85%Added | 2.14%Added | 2.07%Added | 2.03% | 2.06%Added | 2.14%Added |
 Mankind Pharma | – | – | – | – | 2.12% | 2.00%Added | 2.11%Added | 2.13%Added | 2.14%Added | 2.01% | 1.94%Added | 2.10%Added |
Per cent of the fund's net assets at each month end, Oct 2025 to Sep 2026. Under it, the change on the fund's previous month. "After a gap" is a holding after a month with no portfolio on record, so when it was bought is not known; "Not filed" is one gone across such a gap.
Portfolio turnover, per cent of assets a year
- TurnoverPortfolio turnover. How much of the portfolio the fund bought or sold over the last year, as a share of its assets, as the fund house states it. Portfolio turnover in the glossary
Highest 12.0% in Sep 2026
Risk ratios
NAV to 29 Oct 2026
Largest falls
| Largest over | FallLargest fall. The biggest drop in NAV from a high to the low that followed, before the NAV went back above that high. Largest fall in the glossary | High on | Low on | Back at the highBack at the high. The first day the NAV closed at or above the high it had fallen from. Back at the high in the glossary |
|---|---|---|---|---|
| Since Feb 2026 | −9.62% | 23 Sep 2026 | 23 Oct 2026 | Not yet |
Risk level by month
| Months | Fund | BenchmarkBenchmark's risk level. The riskometer level of the fund's benchmark index for the same month, on the same six-step scale as the fund's own. Benchmark's risk level in the glossary |
|---|---|---|
| Jan 2026 to Aug 20268 months | Very High | Very HighNifty500 Healthcare TRI |
The riskometer at each month end, the fund's and its benchmark's. A month with none on record is left out.
Mirae Asset Nifty 500 Healthcare ETF fund managers
Managers now
| Manager | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. Return in the manager's time in the glossary | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. Benchmark over the same days in the glossary | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. Difference from the benchmark in the glossary | Portfolio changed after the handover. How much of the portfolio was different three months after the manager took over: half the sum of every holding's change in weight, with each side's holdings scaled to add up to 100 so a move into cash does not count. Portfolio changed after the handover in the glossary | Portfolio changed before the handover. The same measure over the three months before the manager took over, since portfolios change anyway. Portfolio changed before the handover in the glossary | Assets the manager runs. The latest monthly size of every fund the manager runs now, added up; a fund run with others counts in full for each of its managers, and the line under it counts only the funds they run alone. Assets the manager runs in the glossary | ||
|---|---|---|---|---|---|---|---|---|
| Vishal SinghMs. Ekta Gala (Primary) | Feb 2026 | +10.34%over 257 days | +10.49% | −0.14 pts | – | – | 20 | ₹5,013 Cr |
| Sudip ShereMr. Ritesh Patel (Primary) | Feb 2026 | +10.34%over 257 days | +10.49% | −0.14 pts | – | – | 34 | ₹19,471 Cr |
Returns are the regular plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.
Managers before
| Manager | |||||
|---|---|---|---|---|---|
| Ekta GalaMs. Ekta Gala (Primary) | Feb 2026 | Oct 2026 | +13.06%over 236 days | +13.19% | −0.13 pts |
| Ritesh PatelMr. Ritesh Patel (Primary) | Feb 2026 | Oct 2026 | +13.06%over 236 days | +13.19% | −0.13 pts |
Other funds they run
| Fund | |||||
|---|---|---|---|---|---|
| Mirae Asset Healthcare FundVishal Singh | Oct 2026 | – | – | – | ₹3,494 Cr |
| Mirae Asset Nifty 50 ETFSudip Shere | Oct 2026 | – | – | – | ₹5,217 Cr |
| Mirae Asset Healthcare FundSudip Shere | Oct 2026 | – | – | – | ₹3,494 Cr |
| Mirae Asset Gold ETFSudip Shere | Oct 2026 | – | – | – | ₹3,470 Cr |
| Mirae Asset Nifty Midcap 150 ETFSudip Shere | Oct 2026 | – | – | – | ₹1,818 Cr |
| Mirae Asset Nifty Next 50 ETFSudip Shere | Oct 2026 | – | – | – | ₹1,441 Cr |
| Mirae Asset Silver ETFSudip Shere | Oct 2026 | – | – | – | ₹1,173 Cr |
| Mirae Asset Gold ETF Fund of FundSudip Shere | Oct 2026 | – | – | – | ₹628 Cr |
| Mirae Asset Nifty Metal ETFSudip Shere | Oct 2026 | – | – | – | ₹537 Cr |
| Mirae Asset Nifty Financial Services ETFSudip Shere | Oct 2026 | – | – | – | ₹369 Cr |
The ten largest by assets, by manager. Returns are the regular plan's.
Portfolio overlap
Funds holding the most of the same securities, by weight.
Closest funds in the category
| Portfolio overlap. The share of the two funds' portfolios that is the same: for every holding they share, the smaller of its two weights, added up. Portfolio overlap in the glossary | Shared holdings. The number of securities both funds hold, cash and futures left out. Shared holdings in the glossary | |
|---|---|---|
| Aditya Birla Sun Life Nifty Healthcare ETFAditya Birla Sun Life Mutual Fund | 79.76% | 20 |
| Axis Nifty Healthcare ETFAxis Mutual Fund | 79.76% | 20 |
| Mirae Asset Nifty India Manufacturing ETFMirae Asset Mutual Fund | 18.52% | 11 |
| Mirae Asset Nifty 100 Low Volatility 30 ETFMirae Asset Mutual Fund | 17.60% | 5 |
| Mirae Asset Nifty MidSmallcap400 Momentum Quality 100 ETFMirae Asset Mutual Fund | 17.08% | 14 |
| Mirae Asset BSE Midcap 150 Momentum 30 ETFMirae Asset Mutual Fund | 14.29% | 5 |
| Zerodha Nifty Smallcap 100 ETFZerodha Mutual Fund | 11.79% | 11 |
| Zerodha Nifty Midcap 150 ETFZerodha Mutual Fund | 11.21% | 16 |
| Mirae Asset Nifty Midcap 150 ETFMirae Asset Mutual Fund | 11.20% | 16 |
| UTI Nifty Midcap 150 Exchange Traded FundUTI Mutual Fund | 11.18% | 16 |
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.
Changes to the fund
Newest first.
2026
- 1 AprExpenseExpense ratio stated under the new rules: a base ratio, with brokerage, levies and GST on top
Fund details
Objective
The investment objective of the scheme is to generate returns, before expenses, that are commensurate with the performance of the Nifty 500 Healthcare Total Return Index, subject to tracking error. There is no assurance that the investment objective of the scheme will be achieved.
Asset allocation
- Securities included in Nifty 500 Healthcare Index- 95 to 100% ;
- Money market instruments* including Tri Party REPO/ debt securities, Instruments and/or units of debt/liquid schemes of domestic Mutual Funds- 0 to 5 %
Type of scheme
An open-ended scheme replicating/tracking Nifty 500 Healthcare Total Return Index
- Stated category
- Other Schemes - Exchange Traded Fund (ETF)
- Benchmark
- Nifty 500 Healthcare TRI (Total Return Index)
- Risk level at launch
- Very High
- New fund offer
- 27 Jan 2026 to 6 Feb 2026
- Open for sale again
- 11 Feb 2026
- Price at the offer
- ₹10 a unit
- Minimum at the offer
- ₹5,000
Plans and codes
| Plan | AMFI code | ISIN | First NAV |
|---|---|---|---|
| Regular Growth | 154169 | INF769K01QA6 | 11 Feb 2026 |
This fund
- Scheme information documentThe fund's objective, terms, costs and risks in full
Factsheet
- September 2026 - Passive Fund FactsheetMirae Asset Mutual Fund, Aug 2026
Statement of additional information
- SAI Mirae Asset Mutual FundMirae Asset Mutual Fund, Oct 2026
Annual report
- Mirae Asset Mutual Fund – Annual Report 2025-2026Mirae Asset Mutual Fund, Mar 2026
- Mirae Asset Mutual Fund – Abridged Annual Report 2025-2026Mirae Asset Mutual Fund, Mar 2026
Riskometer disclosure
- Annual Riskometer for the FY 2025-26Mirae Asset Mutual Fund, Mar 2026
Portfolio overlap disclosure
- Portfolio Overlap Report for the month of September 2026Mirae Asset Mutual Fund, Sep 2026